Table 4.

Demographics and clinical characteristics of retreated patients following index nivolumab discontinuation according to their type of retreatment.

	CT and/or TKI subgroup (n = 1,604)	Rechallenge (n = 110)	Resumption (n = 102)	Switch (n = 14)
Median (Q1–Q3) age at nivolumab initiation, years	63.2 (56.6–69.5)	61.5 (54.6–69.0)	66.3 (59.3–72.2)	59.1 (52.9–64.1)
Age ≥75 years at nivolumab initiation, n (%)	146 (9.1)	7 (6.4)	15 (14.7)	1 (7.1)
Male sex, %	66.7	63.6	71.6	71.4
LAM NSCLC diagnosis type, %
De novo	82.2	81.8	68.6	85.7
NSCLC histological subtype, n (%)
Adenocarcinoma	1,076 (67.1)	75 (68.2)	71 (69.6)	11 (78.6)
PD-L1 screening,* %	34.5	37.3	40.2	64.3
PD-L1 screening test result
Positive, %	36.3	43.9	53.7	66.7
If positive (≥1%), category of tumor-activated cells
1% to 49% expression, n (%)	122 (65.6)	9 (60.0)	9 (45.0)	4 (80.0)
≥50% expression, n (%)	64 (34.4)	6 (40.0)	11 (55.0)	1 (20.0)
TNM stage at initial diagnosis, n	1,577	110	100	13
I–III, %	31.8	34.4	38.2	21.4
IV, %	66.6	65.4	59.8	71.4
Not available, %	1.7	0	2	7.1
ECOG performance status at nivolumab initiation, n	901	64	58	7
0, %	24.1	37.5	32.8	28.6
1, %	64.8	54.7	50	57.1
≥2, %	11.1	7.8	17.2	14.3
Location of metastases, %
Brain	37.3	31.3	30.9	53.8

2L+, second line or later; CT, chemotherapy; ECOG, Eastern Cooperative Oncology Group; LAM, locally advanced or metastatic; NSCLC, non-small cell lung cancer; PD-L1, programmed death ligand 1; Q, quartile; TNM, tumor, node, metastasis; TKI, tyrosine kinase inhibitor.

*Any time during the course of the disease.